PLXP - ディペクシウム・ファ―マシュ―ティカルズ (PLx Pharma Inc.) ディペクシウム・ファ―マシュ―ティカルズ

 PLXPのチャート


 PLXPの企業情報

symbol PLXP
会社名 PLx Pharma Inc (ディペクシウム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 PLx Pharma Inc. formerly Dipexium Pharmaceuticals Inc. is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system Aspertec 325 mg PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids such as phospholipids and free fatty acids to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen PL1200 Ibuprofen Capsules 200 mg.   ディペクシウム・ファ―マシュ―ティカルズは、米国の製薬会社。糖尿病性足部潰瘍の軽度な感染症治療のために、「Locilex(ペキシガナン酢酸クリ―ム0.8%)」を開発、商品化に注力する。「Locilex」は、アフリカツメガエルの皮膚から取られ、化学的に合成された22アミノ酸ペプチドであり、後期の臨床段階にある。   PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.
本社所在地 8285 El Rio Street Ste. 130 Houston TX 77054 USA
代表者氏名 Rita M. O Connor リタ・M・O・コナー
代表者役職名 Chief Financial Officer
電話番号 +1 713-842-1249
設立年月日 40179
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 14人
url www.plxpharma.com
nasdaq_url https://www.nasdaq.com/symbol/plxp
adr_tso
EBITDA EBITDA(百万ドル) -13.45220
終値(lastsale) 4.15
時価総額(marketcap) 36253827.3
時価総額 時価総額(百万ドル) 32.23533
売上高 売上高(百万ドル) 0.65163
企業価値(EV) 企業価値(EV)(百万ドル) 21.37565
当期純利益 当期純利益(百万ドル) -10.30847
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 PLx Pharma Inc revenues decreased 34% to $249K. Net income totaled $1.4M vs. loss of $3.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Change in fair value of warrant liabilit increase from $1.7M to $7.4M (income) Interest and other expense decrease of 23% to $559K (expense).

 PLXPのテクニカル分析


 PLXPのニュース

   PLx Pharma Inc. Announces Proposed Public Offering of Common Stock  2021/03/02 16:05:00 Benzinga
SPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a late-stage specialty pharmaceutical company …
   PLx Pharma Shares Rally After FDA Approves Supplemental New Drug Application  2021/03/01 19:27:37 Benzinga
PLx Pharma Inc (NASDAQ: PLXP ) shares were trading higher Monday after the company announced that the U.S. Food and Drug Administration approved a supplemental new drug application for its lead products Vazalore 325 mg and Vazalore 85 mg, the first novel, liquid-filled aspirin capsule. The stock was trading 11.57% higher at $8.29 at last check. PLx Pharma's Technical Levels: PLX Pharma shares hit a low of $5.91 and a high of $17.33 … Full story available on Benzinga.com
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   94 Biggest Movers From Yesterday  2021/02/11 09:04:36 Benzinga
Gainers Anchiano Therapeutics Ltd. (NASDAQ: ANCN ) jumped 187.4% to close at $7.96. Bio-Path Holdings, Inc. (NASDAQ: BPTH ) shares surged 126.4% to close at $11.77 on Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Viant Technology Inc. (NASDAQ: DSP ) climbed 90.9% to close at $47.72 after the company priced 10 million shares at $25 per share to rake in proceeds worth $250 million in an upsized initial public offering (IPO). United States Antimony Corporation (NYSE: UAMY ) climbed 82.6% to close at $1.78 after the company signed non-binding letter of interest regarding the potential supply of antimony with AMBRI. Sundial Growers Inc. (NASDAQ: SNDL ) surged 78.9% to close at $2.95 after jumping over 28% on Tuesday. Tengasco, Inc. (NYSE: TGC ) gained 77.2% to close at $5.05. Tilray, Inc. (NASDAQ: TLRY ) shares gained 50.9% to close at $63.91. Tilray shares jumped more than 40% on Tuesday after the company announced it has entered into an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom.
   Insider Buys PLx Pharma Stock  2020/08/24 11:33:00 Benzinga
A Form 4 filing filed with the SEC on Monday, August 24 showed that OConnor Rita M bought 2,300 shares of PLx Pharma Inc. (NASDAQ: PLXP) at $3.77 on …
   PLx Pharma Inc. to Discuss 2020 Second Quarter Financial Results on August 14, 2020 Conference Call and Provide Business Update  2020/08/05 20:30:00 GlobeNewswire
SPARTA, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company…
   PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call  2020/05/04 10:50:00 GlobeNewswire
SPARTA, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company…
   PLx Pharma Inc. to Present at Biotech Showcase 2020 | MarketScreener  2020/01/07 11:51:04 MarketScreener
SPARTA, N.J., Jan. 07, 2020 -- PLx Pharma Inc. , a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™… | January 7, 2020
   PLx Pharma Provides Regulatory Update on VAZALORE  2020/01/06 14:48:12 Investing News Network
PLx Pharma announced that the US Food and Drug Administration (FDA) is providing clarification for the regulatory path forward for VAZALORE. The post PLx Pharma Provides Regulatory Update on VAZALORE appeared first on Investing News Network .
   Insider Buys PLx Pharma Stock  2020/08/24 11:33:00 Benzinga
A Form 4 filing filed with the SEC on Monday, August 24 showed that OConnor Rita M bought 2,300 shares of PLx Pharma Inc. (NASDAQ: PLXP) at $3.77 on …
   PLx Pharma Inc. to Discuss 2020 Second Quarter Financial Results on August 14, 2020 Conference Call and Provide Business Update  2020/08/05 20:30:00 GlobeNewswire
SPARTA, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company…
   PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call  2020/05/04 10:50:00 GlobeNewswire
SPARTA, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company…
   PLx Pharma Inc. to Present at Biotech Showcase 2020 | MarketScreener  2020/01/07 11:51:04 MarketScreener
SPARTA, N.J., Jan. 07, 2020 -- PLx Pharma Inc. , a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™… | January 7, 2020
   PLx Pharma Provides Regulatory Update on VAZALORE  2020/01/06 14:48:12 Investing News Network
PLx Pharma announced that the US Food and Drug Administration (FDA) is providing clarification for the regulatory path forward for VAZALORE. The post PLx Pharma Provides Regulatory Update on VAZALORE appeared first on Investing News Network .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ディペクシウム・ファ―マシュ―ティカルズ PLXP PLx Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)